Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without ...

A committee in the EU recommended that tolebrutinib, to be sold as Cenrifki, be approved for people with SPMS with no relapses for two years.

The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...

The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...

Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage ...

Late-stage data shows strong relapse reduction versus teriflunomide alongside an imbalance in deaths with no clear pattern identified ...

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...

By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...

Multiple sclerosis MS book and prescription and pen. A blood test might predict relapses in MS Neurofilament light chain levels spike in MS patients’ blood before a relapse However, the prediction ...

For many years, women with multiple sclerosis (MS) were advised not to become pregnant because of concerns about relapses after childbirth. But research now shows that pregnancy doesn't make MS worse, ...

Selma Blair has shared a health update following her Multiple Sclerosis diagnosis. The 53-year-old Legally Blonde star was ...

Antje Ronneberger says symptoms like balance problems means strangers wrongly assume she is drunk.